Osteoprotegerin as a possible marker of diabetes-associated osteoarthritis

Authors

  • Valeriia Orlenko State Institution “V. P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine” Vyshgorodska str., 69, Kyiv, Ukraine, 04114, Ukraine https://orcid.org/0000-0002-8400-576X
  • Kateryna Ivaskiva State Institution “V. P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine” Vyshgorodska str., 69, Kyiv, Ukraine, 04114, Ukraine https://orcid.org/0000-0003-1680-4663

DOI:

https://doi.org/10.15587/2519-4798.2020.203735

Keywords:

diabetes mellitus, diabetes-associated osteoarthritis, osteoprotegerin, metabolic parameters, risk factors

Abstract

Patients with type 1 diabetes have a higher incidence of osteoarthritis and early manifestation than in the general population. The role of insulin deficiency and hyperglycaemia in the initiation of the destructive process has been proven, but the processes of local and systemic regulation of the balance between anabolic and catabolic processes in the joint and their role in the development of diabetes-associated osteoarthritis remain poorly understood.

The aim: to study the role of osteoprotegerin (soluble receptor for tumour necrosis factor - alpha) in the development and progression of diabetes-associated osteoarthritis and its relationship with major metabolic parameters in patients with diabetes mellitus.

Materials and methods. 40 patients with type 1 diabetes (17 men and 23 women) were examined, the mean age of the patients was 38.0±2.0 years, the duration of the diabetes was 18.3±1.9 years, the average level of НВА1с was 8.6±0.3 % and 49 patients with type 2 diabetes mellitus (23 men and 26 women), mean age of patients 61.7±1.3 years, duration of diabetes 12.1±1.1 years, mean level HBa1c 7.6±0.1 %. Arthropathy was established in 70.0±7.3 % patients with type 1 diabetes, in 69.4±6.6 % in patients with type 2 diabetes. By sex and type of diabetes, the proportions of patients with and without arthropathy were not statistically different (p> 0.05). The serum content of osteoprotegerin was determined by ELISA using a kit of reagents from Diaclone (France) and enzyme-linked analyser Stat fax 3200 (USA).

Results. In patients with arthropathy, a significant increase in osteoprotegerin levels was found. The risk of developing arthropathy in patients with type 1 diabetes with an increased levels of osteoprotegerin is 2.3 times higher than at the normal level (relative risk (RR)=2.33; confidence interval (CI 1.42–3.82; p<0.001), in patients with diabetes 2 type – in 1.55 times (RR=1.55; CI 1.16–1.91). Significant differences in the mean osteoprotegerin level were found for groups absent/present arthropathy. A direct correlation between osteoprotegerin and age was found (p<0.01), diabetes mellitus duration (p <0.05); creatinine level (p<0.05), and an inverse correlation was found with glomerular filtration rate (p<0.05). In the absence of arthropathy, osteoprotegerin and fasting glucose were directly correlated in the type 1 diabetes group (p<0.05). Increased osteoprotegerin levels have been shown to be more common in male patients with longer duration of diabetes. In these patients, no renal lesions were detected, but arthropathy was present as a complication of the underlying disease against the background of an increase in HBA1c.

Conclusions. Diabetes-associated osteoarthritis occurs on the background of increased serum osteoprotegerin levels. An increase in the level of osteoprotegerin with an increase in the stage of osteoarthritis was established, so that its level reflects the severity of osteoarthritis. Osteoprotegerin established a direct relationship with the level of creatinine and negatively associated with glomerular filtration rate, i.e. the development and progression of osteoarthritis progression takes place against the background of other vascular complications of diabetes, in particular diabetic nephropathy. An increase in osteoprotegerin is more typical for male patients and depends on the duration of diabetes

Author Biographies

Valeriia Orlenko, State Institution “V. P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine” Vyshgorodska str., 69, Kyiv, Ukraine, 04114

PhD, Head of Department

Scientific Advisory Department of Ambulatory and Preventive Care in Patients with Endocrine Disorders

Kateryna Ivaskiva, State Institution “V. P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine” Vyshgorodska str., 69, Kyiv, Ukraine, 04114

PhD, Senior Researcher

Scientific Advisory Department of Ambulatory and Preventive Care in Patients with Endocrine Disorders

References

  1. Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., Malanda, B. (2018). IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Research and Clinical Practice, 138, 271–281. doi: http://doi.org/10.1016/j.diabres.2018.02.023
  2. Louati, K., Vidal, C., Berenbaum, F., Sellam, J. (2015). Association between diabetes mellitus and osteoarthritis: systematic literature review and meta-analysis. RMD Open, 1 (1), e000077–e000077. doi: http://doi.org/10.1136/rmdopen-2015-000077
  3. King, K. B., & Rosenthal, A. K. (2015). The adverse effects of diabetes on osteoarthritis: update on clinical evidence and molecular mechanisms. Osteoarthritis and Cartilage, 23(6), 841–850. doi:10.1016/j.joca.2015.03.031
  4. Magnusson, K., Hagen, K. B., Østerås, N., Nordsletten, L., Natvig, B., Haugen, I. K. (2015). Diabetes Is Associated With Increased Hand Pain in Erosive Hand Osteoarthritis: Data From a Population-Based Study. Arthritis Care & Research, 67 (2), 187–195. doi: http://doi.org/10.1002/acr.22460
  5. Pantsulaia, I., Kalichman, L., Kobyliansky, E. (2010). Association between radiographic hand osteoarthritis and RANKL, OPG and inflammatory markers. Osteoarthritis and Cartilage, 18 (11), 1448–1453. doi: http://doi.org/10.1016/j.joca.2010.06.009
  6. Tat, S. K., Pelletier, J.-P., Velasco, C. R., Padrines, M., Martel-Pelletier, J. (2009). New Perspective in Osteoarthritis: The OPG and RANKL System as a Potential Therapeutic Target? The Keio Journal of Medicine, 58 (1), 29–40. doi: http://doi.org/10.2302/kjm.58.29
  7. Bolon, B., Grisanti, M., Villasenor, K., Morony, S., Feige, U., Simonet, W. S. (2015). Generalized Degenerative Joint Disease in Osteoprotegerin (Opg) Null Mutant Mice. Veterinary Pathology, 52 (5), 873–882. doi: http://doi.org/10.1177/0300985815586221
  8. Ma, Y., Yan, L., Xu, H., Tao, Y., Chen, S., Zhu, J., Xie, L. (2017). Involvement of miR-145 in osteoarthritis pathogenesis via inducing OPG expression in osteoclasts. International Journal of Clinical and Experimental Medicine, 10 (2), 3225–3230.
  9. Boyce, B. F., Xing, L. (2007). Biology of RANK, RANKL, and osteoprotegerin. Arthritis Research & Therapy, 9 (1), 1. doi: http://doi.org/10.1186/ar2165
  10. Yoshimura, N., Muraki, S., Oka, H., Tanaka, S., Kawaguchi, H., Nakamura, K., Akune, T. (2012). Accumulation of metabolic risk factors such as overweight, hypertension, dyslipidaemia, and impaired glucose tolerance raises the risk of occurrence and progression of knee osteoarthritis: a 3-year follow-up of the ROAD study. Osteoarthritis and Cartilage, 20 (11), 1217–1226. doi: http://doi.org/10.1016/j.joca.2012.06.006
  11. Van Campenhout, A., Golledge, J. (2009). Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis, 204 (2), 321–329. doi: http://doi.org/10.1016/j.atherosclerosis.2008.09.033
  12. Del Fattore, A., Teti, A. (2012). The Tight Relationship Between Osteoclasts and the Immune System. Inflammation & Allergy-Drug Targets, 11 (3), 181–187. doi: http://doi.org/10.2174/187152812800392733
  13. Schoppet, M., Sattler, A. M., Schaefer, J. R., Herzum, M., Maisch, B., Hofbauer, L. C. (2003). Increased Osteoprotegerin Serum Levels in Men with Coronary Artery Disease. The Journal of Clinical Endocrinology & Metabolism, 88 (3), 1024–1028. doi: http://doi.org/10.1210/jc.2002-020775
  14. Crisafulli, A., Romeo, A., Floccari, F., Aloisi, E., Atteritano, M., Cincotta, M. et. al. (2005). Osteoprotegerin and Bone Mineral Density in Hemodiafiltration Patients. Renal Failure, 27 (5), 531–539. doi: http://doi.org/10.1080/08860220500198698
  15. Andersen, G. O., Knudsen, E. C., Aukrust, P., Yndestad, A., Oie, E., Muller, C. et. al. (2011). Elevated serum osteoprotegerin levels measured early after acute ST-elevation myocardial infarction predict final infarct size. Heart, 97 (6), 460–465. doi: http://doi.org/10.1136/hrt.2010.206714
  16. Berenbaum, F. (2011). Diabetes-induced osteoarthritis: from a new paradigm to a new phenotype. Annals of the Rheumatic Diseases, 70 (8), 1354–1356. doi: http://doi.org/10.1136/ard.2010.146399
  17. Majjad, A., Errahali, Y., Toufik, H., H Djossou, J., Ghassem, M. A., Kasouati, J., Maghraoui, A. E. (2018). Musculoskeletal Disorders in Patients with Diabetes Mellitus: A Cross-Sectional Study. International Journal of Rheumatology, 2018, 1–6. doi: http://doi.org/10.1155/2018/3839872
  18. Povorozniuk, V. V. (2014). Zakhvoriuvannia kistkovo-miazovoi systemy v liudei riznoho viku (vybrani lektsii, ohliady, statti). Vol. 4. Kyiv, 672.

Downloads

Published

2020-05-31

How to Cite

Orlenko, V., & Ivaskiva, K. (2020). Osteoprotegerin as a possible marker of diabetes-associated osteoarthritis. ScienceRise: Medical Science, (3 (36), 25–32. https://doi.org/10.15587/2519-4798.2020.203735

Issue

No. 3 (36) (2020)

Section

Medical Science

License

Copyright (c) 2020 Valeriia Orlenko, Kateryna Ivaskiva

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.